<DOC>
	<DOC>NCT02915510</DOC>
	<brief_summary>This study will evaluate the safety, gastrointestinal (GI) tolerance, acceptability and compliance of a Glycomacropeptide-based protein substitute for patients with Phenylketonuria (PKU).</brief_summary>
	<brief_title>GMP Drink for PKU Study</brief_title>
	<detailed_description />
	<mesh_term>Phenylketonurias</mesh_term>
	<criteria>Male or female Over 3 years of age Diagnosed with classical or variant type phenylketonuria Have been compliant in taking at least one amino acidbased, Phefree protein substitute, providing at least 20g protein equivalents, for at least 1 month prior to trial commencement Have a prescribed daily Phe allowance Written informed consent from patient, or from parent / carer if applicable Currently prescribed Sapropterin or similar tetrahydrobiopterin based medication Pregnant or lactating Requiring parenteral nutrition Major hepatic or renal dysfunction Participation in other studies within 1 month prior to entry of this study Allergy to any of the study product ingredients, including milk protein or soya Investigator concern around willingness/ability of patient or parent/carer to comply with protocol requirements</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>